<DOC>
	<DOCNO>NCT01645735</DOCNO>
	<brief_summary>The purpose study determine whether ceftaroline effective safe treatment patient Community-acquired Bacterial Pneumonia ( CABP ) risk infection due Methicillin-resistant Staphylococcus aureus ( MRSA ) .</brief_summary>
	<brief_title>Evaluation Ceftaroline Fosamil Versus Comparator Adult Subjects With Community-acquired Bacterial Pneumonia ( CABP ) With Risk Methicillin-resistant Staphylococcus Aureus</brief_title>
	<detailed_description>A Multicenter , Multinational , Randomized , Double-blind Study Evaluate Efficacy safety Ceftaroline fosamil Versus Ceftriaxone Plus Vancomycin Adult Subjects Community-acquired Bacterial Pneumonia Risk Infection Due Methicillin-resistant Staphylococcus aureus .</detailed_description>
	<mesh_term>Infection</mesh_term>
	<mesh_term>Pneumonia</mesh_term>
	<mesh_term>Staphylococcal Infections</mesh_term>
	<mesh_term>Pneumonia , Bacterial</mesh_term>
	<mesh_term>Ceftriaxone</mesh_term>
	<mesh_term>Vancomycin</mesh_term>
	<mesh_term>Methicillin</mesh_term>
	<mesh_term>Cephalosporins</mesh_term>
	<criteria>Subjects require meet All follow inclusion criterion : 1 . Male female , ≥ 18 year old 2 . Presence CABP require hospitalization 3 . Presence CABP meeting follow criterion : I. confirm pneumonia ( new progressive pulmonary ) II . Acute illness ( ≤ 7 day ' duration ) least 3 clinical sign symptom consistent low respiratory tract infection MRSA Risk Factors • MRSApositive blood culture respiratory specimen risk factor MRSA history colonization MRSA Subjects must Not meet follow exclusion criterion baseline : 1 . History hypersensitivity allergic reaction βlactam antimicrobial 2 . Suspected microbiologicallydocumented infection pathogen know resistant study drug 3 . Noninfectious cause pulmonary infiltrates ( eg , pulmonary embolism , chemical pneumonitis aspiration , hypersensitivity pneumonia , congestive heart failure ) 4 . More 24 hour potentially effective systemic antibacterial therapy CABP within 96 hour randomization 5 . Endstage renal disease [ Creatinine Clearance ( CrCl ) &lt; 15 ] , include hemodialysis 6 . Evidence significant hepatic , hematological , immunocompromising condition</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2015</verification_date>
	<keyword>Infections</keyword>
	<keyword>Teflaro</keyword>
	<keyword>cephalosporin</keyword>
	<keyword>Ceftaroline</keyword>
	<keyword>antibiotic</keyword>
	<keyword>pneumonia</keyword>
</DOC>